by Symmetron | Jan 18, 2019
Idiopathic Pulmonary Fibrosis Pharmacoeconomic Assessment of Nintedanib For The Treatment of Idiopathic Pulmonary Fibrosis In The Greek Healthcare System Presented at ISPOR Europe. October 29 to November 2, 2016. Vienna, Austria. Authors Triaki G, Souliotis K, Bouros...
by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use PharmacoEconomics Open (2018) 1-10 Authors Diamantopoulos A, Maher TM, Esser D, LeReun C Process \ Retrospective analysis of resource use data...
by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK PharmacoEconomics. 2017 Apr;35(4):479-491 Authors Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A Process \ An...
by Symmetron | Jan 17, 2019
Idiopathic Pulmonary Fibrosis The burden of illness of idiopathic pulmonary fibrosis:a comprehensive evidence review PharmacoEconomics. 2018;36:779–807 Awards Top PharmacoEconomics article of 2018! Downloads and counting Authors Diamantopoulos A, Wright E,...
Recent Comments